MX2015015249A - Peptidos terapeuticos. - Google Patents

Peptidos terapeuticos.

Info

Publication number
MX2015015249A
MX2015015249A MX2015015249A MX2015015249A MX2015015249A MX 2015015249 A MX2015015249 A MX 2015015249A MX 2015015249 A MX2015015249 A MX 2015015249A MX 2015015249 A MX2015015249 A MX 2015015249A MX 2015015249 A MX2015015249 A MX 2015015249A
Authority
MX
Mexico
Prior art keywords
pyy
therapeutic peptides
novel
analogs
obesity
Prior art date
Application number
MX2015015249A
Other languages
English (en)
Inventor
Steven Thomas Dock
Andrew James Carpenter
Robert Neil Hunter Iii
Yulin Wu
Ved P Srivastava
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MX2015015249A publication Critical patent/MX2015015249A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones

Abstract

La presente invención se refiere a análogos novedosos de PYY que tienen un perfil terapéutico mejorado cuando se comparan con PYY nativo de humano. Estos análogos de PYY novedosos útiles en el tratamiento de obesidad, diabetes, y otros trastornos.
MX2015015249A 2013-05-02 2014-04-30 Peptidos terapeuticos. MX2015015249A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361818624P 2013-05-02 2013-05-02
PCT/IB2014/061123 WO2014178018A1 (en) 2013-05-02 2014-04-30 Therapeutic peptides

Publications (1)

Publication Number Publication Date
MX2015015249A true MX2015015249A (es) 2016-02-09

Family

ID=50842285

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015249A MX2015015249A (es) 2013-05-02 2014-04-30 Peptidos terapeuticos.

Country Status (20)

Country Link
US (2) US20160108098A1 (es)
EP (1) EP2992008B1 (es)
JP (1) JP2016519130A (es)
KR (1) KR20160003848A (es)
CN (1) CN105263957A (es)
AR (1) AR096162A1 (es)
AU (1) AU2014261111B2 (es)
BR (1) BR112015027528B1 (es)
CA (1) CA2909045C (es)
CL (1) CL2015003199A1 (es)
EA (1) EA201591839A1 (es)
ES (1) ES2732291T3 (es)
HK (1) HK1214829A1 (es)
MX (1) MX2015015249A (es)
PE (1) PE20151808A1 (es)
RU (1) RU2015144632A (es)
SG (1) SG11201508469YA (es)
TW (1) TW201534616A (es)
UY (1) UY35548A (es)
WO (1) WO2014178018A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3326620T3 (da) 2010-12-16 2020-05-25 Novo Nordisk As Faste sammensætninger omfattende en glp-1-agonist og et salt af n-(8-(2- hydroxybenzoyl)amino)caprylsyre
AU2013234496B2 (en) 2012-03-22 2017-07-27 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
AU2014261111B2 (en) * 2013-05-02 2017-03-16 Glaxosmithkline Intellectual Property Development Limited Therapeutic peptides
US10583172B2 (en) 2013-11-15 2020-03-10 Novo Nordisk A/S HPYY(1-36) having a beta-homoarginine substitution at position 35
EP3068421B1 (en) 2013-11-15 2019-04-17 Novo Nordisk A/S Selective pyy compounds and uses thereof
WO2016124687A1 (en) * 2015-02-04 2016-08-11 Novo Nordisk A/S Selective pyy compounds and uses thereof
CN107849110B (zh) 2015-06-12 2021-11-26 诺和诺德股份有限公司 选择性pyy化合物及其用途
WO2017115853A1 (ja) * 2015-12-28 2017-07-06 出光興産株式会社 ペプチドタグおよびそれを含むタグ付加タンパク質
JOP20190097A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv الجلوبولينات المناعية واستخداماتها
US20200188479A1 (en) 2017-03-08 2020-06-18 Intarcia Therapeutics, Inc. Apparatus and methods for administration of a nauseogenic compound from a drug delivery device
IL275778B2 (en) 2018-02-02 2023-12-01 Novo Nordisk As Solid compounds that make up glp-1 agonist n-8-2-hydroxybenzoyl salt
US11780900B2 (en) 2018-04-25 2023-10-10 Janssen Sciences Ireland Unlimited Company Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
TW202208410A (zh) * 2018-11-01 2022-03-01 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
PE20221168A1 (es) 2019-11-11 2022-07-25 Boehringer Ingelheim Int Agonistas del receptor npy2
EP4069726A4 (en) * 2019-12-04 2024-03-20 Scripps Research Inst GLP2 RECEPTOR AGONISTS AND METHOD OF USE
US11739134B2 (en) * 2020-04-17 2023-08-29 Intarcia Therapeutics, Inc. Long acting peptide tyrosine tyrosine (PYY) analogs and methods of use
CR20230074A (es) 2020-08-07 2023-04-19 Boehringer Ingelheim Int Agonistas del receptor npy2 solubles
US20240091318A1 (en) 2022-08-18 2024-03-21 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists
CN115960258B (zh) * 2022-09-30 2024-01-12 广西医科大学附属肿瘤医院 一类GLP-1/glucagon/Y2受体三重激动剂及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
DK134189D0 (da) 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
CA2073856C (en) 1990-01-24 2002-12-03 Douglas I. Buckley Glp-1 analogs useful for diabetes treatment
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US6413539B1 (en) 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US5612051A (en) 1995-11-17 1997-03-18 Yue; Samuel K. Method of treating involuntary muscle dysfunction with relaxin hormone
CA2262647C (en) 1996-08-08 2007-12-04 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
PT1019077E (pt) 1997-08-08 2008-02-21 Amylin Pharmaceuticals Inc Novos compostos agonistas de exendina
US6117949A (en) 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
DK1032587T4 (da) 1997-11-14 2013-04-08 Amylin Pharmaceuticals Llc Hidtil ukendte exendinagonist-forbindelser
JP2003522721A (ja) 1997-11-14 2003-07-29 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規なエキセンジンアゴニスト化合物
ATE366115T1 (de) 1998-02-13 2007-07-15 Amylin Pharmaceuticals Inc Inotropische und diuretische effekte von exendin und glp-1
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
KR100867392B1 (ko) 2000-08-15 2008-11-06 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 마이크로입자
DE60230818D1 (de) * 2001-09-24 2009-02-26 Imp Innovations Ltd Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit
CA2555894A1 (en) * 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
JP2008514616A (ja) * 2004-09-24 2008-05-08 メルク エンド カムパニー インコーポレーテッド 肥満の治療のための組合せ療法
EP3000826A1 (en) * 2004-12-13 2016-03-30 Amylin Pharmaceuticals, LLC Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
GB0504857D0 (en) * 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
EA200870365A1 (ru) * 2006-03-23 2009-02-27 Амилин Фармасьютикалз, Инк. Эндотелин и агонисты рецепторов к эндотелину в лечении заболеваний обмена веществ
EA201290123A1 (ru) 2009-09-30 2012-10-30 Глаксо Груп Лимитед Продукты слияния и конъюгаты лекарственных средств с увеличенным периодом полувыведения
WO2011050008A2 (en) * 2009-10-19 2011-04-28 Amylin Pharmaceuticals, Inc. Combination therapy comprising administration of an amylinomimetic and a pyy peptidomimetic for effecting weight loss and for treating obesity and related metabolic conditions and disorders
GB201001333D0 (en) * 2010-01-27 2010-03-17 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
JO3131B1 (ar) 2010-04-27 2017-09-20 Glaxosmithkline Llc مركبات كيميائية
EP2600887A4 (en) * 2010-07-09 2014-01-22 Amylin Pharmaceuticals Llc MICROCRYSTALLINE AGONISTS OF Y-RECEPTORS
GB201101459D0 (en) * 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
AU2014261111B2 (en) * 2013-05-02 2017-03-16 Glaxosmithkline Intellectual Property Development Limited Therapeutic peptides
EP3068421B1 (en) * 2013-11-15 2019-04-17 Novo Nordisk A/S Selective pyy compounds and uses thereof

Also Published As

Publication number Publication date
TW201534616A (zh) 2015-09-16
UY35548A (es) 2014-11-28
AU2014261111A1 (en) 2015-11-19
WO2014178018A1 (en) 2014-11-06
AU2014261111B2 (en) 2017-03-16
US20140329742A1 (en) 2014-11-06
CL2015003199A1 (es) 2016-05-06
EA201591839A1 (ru) 2016-05-31
KR20160003848A (ko) 2016-01-11
AR096162A1 (es) 2015-12-09
EP2992008B1 (en) 2019-04-10
US9441023B2 (en) 2016-09-13
CN105263957A (zh) 2016-01-20
RU2015144632A (ru) 2017-06-07
US20160108098A1 (en) 2016-04-21
ES2732291T3 (es) 2019-11-21
BR112015027528A2 (pt) 2017-12-05
HK1214829A1 (zh) 2016-08-05
PE20151808A1 (es) 2015-12-16
CA2909045A1 (en) 2014-11-06
JP2016519130A (ja) 2016-06-30
SG11201508469YA (en) 2015-11-27
CA2909045C (en) 2022-12-06
EP2992008A1 (en) 2016-03-09
BR112015027528B1 (pt) 2023-02-14

Similar Documents

Publication Publication Date Title
MX2015015249A (es) Peptidos terapeuticos.
JOP20200192A1 (ar) أجسام مضادة لـ tigit
MX2016013243A (es) Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4.
PH12016500675A1 (en) Acylated glucagon analogues
MX2016013244A (es) Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon.
MX2014015423A (es) Analogos de peptido de exedina-4.
MX2016004907A (es) Analogos del glucagon.
MX2017005834A (es) Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
MX2016013248A (es) Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4.
MX2015008114A (es) Derivados de exendina-4.
BR112016023948A2 (pt) proteínas fc multiméricas
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
MX2018000362A (es) Derivados de exendina-4 como agonistas peptidicos duales selectivos de los receptores de glp-1/glucagon.
MX2016010953A (es) Proteinas de fc multimericas.
EP3148569A4 (en) Therapeutic tratment of skin disease with recombinant commensal skin microorganisms
MX366636B (es) Nuevo derivado de un análogo de insulina.
EA201691567A1 (ru) Способы лечения легких травм головного мозга
UA117933C2 (uk) Поліпептид, здатний зв'язувати с5-компонент комплементу людини
PH12017501290A1 (en) Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
PH12017501979A1 (en) Pharmaceutical compound
EA201691220A1 (ru) Способ для получения композиции пегилированных белков
PH12014000104A1 (en) Therapeutic methods and compositions for treating diabetes
GB201304462D0 (en) Therapeutic vaccine for treatment of type 2 diabetes and impaired glucose tolerance